Skip to main content
All lobbying filings

CARDINAL HEALTH, INC.

CARDINAL HEALTH, INC. filed a Q1 report for CARDINAL HEALTH INC on April 20, 2026.

Lobbying for CARDINAL HEALTH INC

All filings by CARDINAL HEALTH, INC. · Everything CARDINAL HEALTH INC has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$1,320,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Ohio

Official filing document

 Government bodies contacted 10

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

Issues related to drug pricing, bona fide service fees, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine; Issues related to provider reimbursement, Medicare and Medicaid, workforce shortages, and product shortages; Issues related to Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS), competitive bidding, reimbursement to home health agencies, and acute hospital care at home services; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5031/S. 3159, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164/S. 2426, Ensuring Community Access to Pharmacist Services Act; Education around issues facing independent physicians, including S.3822, the Break Up Big Medicine Act.

Manufacturing

Education on supply chain issues, drug shortages, domestic manufacturing, medical device environmental issues; Issues related to the medical supply chain and transportation.

Trade (domestic/foreign)

Issues related to tariffs, trade, and U.S. trade policy.

Tariff (miscellaneous tariff bills)

Issues related to tariffs, trade, and U.S. trade policy.

 Bills named in this filing 6
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • H.R. 5031
    Preserving Patient Access to Long-Term Care Pharmacies Act
  • S. 3159
    Preserving Patient Access to Long-Term Care Pharmacies Act
  • H.R. 3164
    Ensuring Community Access to Pharmacist Services Act
  • S. 2426
    Equitable Community Access to Pharmacist Services Act
  • S. 3822
    Break Up Big Medicine Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem